1. Scrip
  2. >>New Products

Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price

 
• By Emily Hayes

CD33 inhibiting drug that was yanked from the market in 2010 due to reports of veno-occlusive disease is now fully approved by the US FDA at a lower recommended dose.

Pfizer Inc.'santibody-drug conjugateMylotarg is set to reenter the US market at the list price of $24,600 for one cycle of treatment, which is all many patients will need, the company said.

The US FDA cleared Mylotarg (gemtuzumab ozagamicin) Sept. 1 for adults with newly-diagnosed, CD33-positive acute myeloid leukemia (AML) and children...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 
• By Jessica Merrill

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

More from Scrip

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Can Bayer’s Pharmaceuticals Division Help It Weather A Perfect Storm?

 
• By Aakash Babu

Bayer continues to keep faith in its pharmaceuticals business despite a plethora of problems for the wider group with job cuts, continued debt concerns and ongoing glyphosate litigation claims.

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By Manas Mishra

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.